Targeted drug tested for indian lung cancer patients with rare mutation
NCT ID NCT05110196
Summary
This study tested the safety and effectiveness of the drug capmatinib for Indian adults with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called a MET exon 14 skipping mutation. About 50 patients took capmatinib pills twice daily for 24 weeks. The main goal was to monitor side effects and see how well the drug worked to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Gujarat, Gujarat, 380016, India
-
Novartis Investigative Site
Mangalore, Karnataka, 575002, India
-
Novartis Investigative Site
Thalassery, Kerala, 670103, India
-
Novartis Investigative Site
Trivandrum, Kerala, 695 011, India
-
Novartis Investigative Site
Bhopal, Madhya Pradesh, 462001, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400 012, India
-
Novartis Investigative Site
Mumbai, Maharashtra, 400056, India
-
Novartis Investigative Site
Nagpur, Maharashtra, 441108, India
-
Novartis Investigative Site
Pune, Maharashtra, 411040, India
-
Novartis Investigative Site
New Delhi, National Capital Territory of Delhi, 110029, India
-
Novartis Investigative Site
Bhubaneshwar, Odisha, 751007, India
-
Novartis Investigative Site
Hyderabad, Telangana, 500004, India
-
Novartis Investigative Site
Varanasi, Uttar Pradesh, 221005, India
-
Novartis Investigative Site
Kolkata, West Bengal, 700 020, India
-
Novartis Investigative Site
Puducherry, 605006, India
Conditions
Explore the condition pages connected to this study.